Molecular characterization of NF1-mutated NSCLC and clinical outcomes


Christopher Gates, Andrew Elliott, Hossein Borghaei, Konstantinos Sdrimas, Joanne Xiu, Phillip Walker, Ari M. Vanderwalde, Stephen V. Liu, Jean Gabriel Bustamante Alvarez

Key Finding:

Non-small cell lung cancer patients with mutant NF1 rarely harbor actionable driver co-alterations, but they do show increased activation of the RAS-MAPK axis, which may represent a pathway to target with MEK inhibitors. 

Download Publication